OF THE
TIMES
This website was launched by the European Medicines Agency in 2012 to provide public access to reports of suspected side effects (also known as suspected adverse drug reactions). These reports are submitted electronically to EudraVigilance by national medicines regulatory authorities and by pharmaceutical companies that hold marketing authorisations (licences) for the medicines.
EudraVigilance is a system designed for collecting reports of suspected side effects. These reports are used for evaluating the benefits and risks of medicines during their development and monitoring their safety following their authorisation in the European Economic Area (EEA). EudraVigilance has been in use since December 2001.
This website was launched to comply with the EudraVigilance Access Policy, which was developed to improve public health by supporting the monitoring of the safety of medicines and to increase transparency for stakeholders, including the general public.
The Management Board of the European Medicines Agency first approved the EudraVigilance Access Policy in December 2010. A revision was adopted by the Board in December 2015 based on the 2010 pharmacovigilance legislation. The policy aims to provide stakeholders such as national medicines regulatory authorities in the EEA, the European Commission, healthcare professionals, patients and consumers, as well as the pharmaceutical industry and research organisations, with access to reports on suspected side effects.
Transparency is a key guiding principle of the Agency, and is pivotal to building trust and confidence in the regulatory process. By increasing transparency, the Agency is better able to address the growing need among stakeholders, including the general public, for access to information. (Source.)
In October 2014, the WHO's Strategic Advisory Group of Experts (SAGE) published an extensive report on vaccine hesitancy, looking at different approaches to help shape the public's behavior toward vaccination.24 The report specifically explored marketing strategies employed by other organizations such as the International Food and Beverage Alliance (IFBA), which includes companies like Coca Cola Company, Pepsico and McDonalds...
According to newspaper columnist Lawrence Solomon, "The World Health Organization Working Group recommended that this fact-free, emotion-laden Coca-Cola style marketing strategy be urged on the international "pro-vaccination lobbies." He added, "Aided by this 'Keep It Simple, Stupid' strategy, WHO is hopeful that the marketing wizardry that works for the food and beverage giants will help the pro-vaccination movement overcome the public's reluctance to vaccinate."24
Human rhinovirus triggers an innate immune response that blocks SARS-CoV-2 replication within the human respiratory epithelium. Given the high prevalence of human rhinovirus, this interference effect might cause a population-wide reduction in the number of new COVID-19 infections.
From a host's perspective, HRV [Human Rhinovirus] infections, which are usually associated with mild disease, stimulate an antiviral response that prevents infections by more severe (and sometimes lethal) viruses such as SARS-CoV-2.


José Baselga, a storied oncology researcher and pharmaceutical executive whose discoveries helped pave the way for new breast cancer therapies, died Sunday at the age of 61.See also:
His death was confirmed by AstraZeneca, where Baselga had been serving as executive vice president for research and development in oncology. The company did not provide a cause of death; the Spanish newspaper La Vanguardia reported it was Creutzfeldt-Jakob disease, a rare brain infection that causes degeneration and death.
Comment: See also: